Welsh Government has approved advice from the All Wales Medicines Strategy Group (AWMSG) for one new medicine.
Levodopa-carbidopa-entacapone (Lecigon®) is recommended for restricted use in NHS Wales to treat advanced Parkinson’s disease when oral medicines (medicines taken by mouth) no longer produce sufficient effect. Levodopa-carbidopa-entacapone (Lecigon®) is only recommended for patients for whom treatment with deep brain stimulation is not suitable.
Levodopa-carbidopa-entacapone (Lecigon®) is not yet marketed in the UK, AWTTC will update this advice when they get confirmation that the product is launched.
AWTTC’s Patient Access to Medicines Service (PAMS) supports the AWMSG to assess and monitor new medicines in Wales.